Literature DB >> 22543705

Protective effects of tiopronin against high fat diet-induced non-alcoholic steatohepatitis in rats.

Jian-qing Wang1, Yu-hong Zou, Cheng Huang, Chao Lu, Lei Zhang, Yong Jin, Xiong-wen Lü, Li-ping Liu, Jun Li.   

Abstract

AIM: To study the protective effects of tiopronin against high fat diet-induced non-alcoholic steatohepatitis in rats.
METHODS: Male Sprague-Dawley rats were given a high-fat diet for 10 weeks. The rats were administered tiopronin (20 mg/kg) or a positive control drug ursodeoxycholic acid (UDCA, 15 mg/kg) via gavage daily from week 5 to week 10. After the rats were sacrificed, serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), free fatty acids (FFA), high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C), and liver homogenate FFA, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and malondialdehyde (MDA) were measured using commercial analysis kits. The expression levels of CYP2E1 mRNA and protein were determined using RT-PCR and immunoblot assays, respectively.
RESULTS: Tiopronin significantly lowered both the serum ALT and AST levels, while only the serum ALT level was lowered by UDCA. Tiopronin significantly decreased the serum and liver levels of TG, TC and FFA as well as the serum LDL-C level, and increased the serum HDL-C level, while UDCA decreased the serum and liver TC levels as well as the serum LDL-C level, but did not change the serum levels of TG, FFA and HDL-C. Tiopronin apparently ameliorated the hepatocyte degeneration and the infiltration of inflammatory cells in the livers, but UDCA did not affect the pathological features of the livers. Both tiopronin and UDCA ameliorated the mitochondrial abnormality in the livers. The benefits of tiopronin were associated with increased SOD and GSH-Px activities, and with decreased MDA activity and CYP2E1 expression in the livers.
CONCLUSION: Tiopronin exerts protective effects against non-alcoholic steatohepatitis in rats, which may be associated with its antioxidant properties and regulation of lipid metabolism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543705      PMCID: PMC4010369          DOI: 10.1038/aps.2012.19

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  37 in total

1.  High-fat emulsion-induced rat model of nonalcoholic steatohepatitis.

Authors:  Yuhong Zou; Jun Li; Chao Lu; Jianqing Wang; Jinfang Ge; Yan Huang; Lei Zhang; Yuanyuan Wang
Journal:  Life Sci       Date:  2006-03-24       Impact factor: 5.037

Review 2.  Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.

Authors:  F H Luyckx; P J Lefebvre; A J Scheen
Journal:  Diabetes Metab       Date:  2000-04       Impact factor: 6.041

Review 3.  Mitochondrial respiratory chain disorders and the liver.

Authors:  A A Morris
Journal:  Liver       Date:  1999-10

4.  Effect of tiopronin on senile cataracts. A double-blind clinical study.

Authors:  H Ichikawa; K Imaizumi; Y Tazawa; Y Obara; Y Ishikawa; I Tobari; Y Tanabe
Journal:  Ophthalmologica       Date:  1980       Impact factor: 3.250

5.  [Long-term tolerability of tiopronin (Acadione) in the treatment of rheumatoid arthritis. Apropos of 140 personal cases].

Authors:  J Sany; B Combe; D Verdie-Petibon; A Tagemouati; J P Daures
Journal:  Rev Rhum Mal Osteoartic       Date:  1990-02

6.  Thioacetamide-induced hepatic damage in a rat nutritional model of steatohepatitis.

Authors:  Yona Avni; Haim Shirin; Hussein Aeed; Mark Shahmurov; Shlomo Birkenfeld; Rafael Bruck
Journal:  Hepatol Res       Date:  2004-11       Impact factor: 4.288

7.  Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation.

Authors:  M D Weltman; G C Farrell; C Liddle
Journal:  Gastroenterology       Date:  1996-12       Impact factor: 22.682

8.  Non-alcoholic steatohepatitis: review of a growing medical problem.

Authors:  K. Te Sligte; I. Bourass; J.P. Sels; A. Driessen; R.W. Stockbrugger; G.H. Koek
Journal:  Eur J Intern Med       Date:  2004-02       Impact factor: 4.487

9.  The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity.

Authors:  ZhengZheng Li; Michael Berk; Thomas M McIntyre; Gregory J Gores; Ariel E Feldstein
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

10.  Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies.

Authors:  Richard Kirsch; Vivian Clarkson; Enid G Shephard; David A Marais; Mohamed A Jaffer; Vivienne E Woodburne; Ralph E Kirsch; Pauline de la M Hall
Journal:  J Gastroenterol Hepatol       Date:  2003-11       Impact factor: 4.029

View more
  5 in total

1.  Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma.

Authors:  Jianhua Li; Xinguang Qiu; Wenzhi Guo; Bing Yan; Shuijun Zhang
Journal:  Med Oncol       Date:  2015-09-02       Impact factor: 3.064

2.  Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage.

Authors:  Qi-Sheng Ling; Sai-Long Zhang; Jia-Sheng Tian; Ming-He Cheng; Ai-Jun Liu; Feng-Hua Fu; Jian-Guo Liu; Chao-Yu Miao
Journal:  Acta Pharmacol Sin       Date:  2021-05-17       Impact factor: 7.169

3.  Pediococcus acidilactici FZU106 alleviates high-fat diet-induced lipid metabolism disorder in association with the modulation of intestinal microbiota in hyperlipidemic rats.

Authors:  Qing Zhang; Wei-Ling Guo; Gui-Mei Chen; Min Qian; Jin-Zhi Han; Xu-Cong Lv; Li-Jiao Chen; Ping-Fan Rao; Lian-Zhong Ai; Li Ni
Journal:  Curr Res Food Sci       Date:  2022-04-27

4.  Hypolipidemic effect of gypenosides in experimentally induced hypercholesterolemic rats.

Authors:  Yue-Hui Yang; Jun Yang; Qing-Hua Jiang
Journal:  Lipids Health Dis       Date:  2013-10-25       Impact factor: 3.876

5.  Efficiency and safety evaluation of prophylaxes for venous thrombosis after gynecological surgery.

Authors:  Ruidi Yu; Faridah Nansubuga; Jun Yang; Wencheng Ding; Kezhen Li; Danhui Weng; Peng Wu; Gang Chen; Ding Ma; Juncheng Wei
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.